Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

This study is testing a maintenance therapy regimen — combining decitabine, venetoclax, and blinatumomab (three cancer drugs) — to prevent relapse after a stem cell transplant in people with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (B-ALL), a type of blood cancer. **You may be eligible if...** - You have Ph-negative B-cell ALL and have undergone an allogeneic stem cell transplant (using a donor's cells) - You are at least 3 months post-transplant with your blood counts recovering - You have no detectable leukemia remaining (confirmed by sensitive blood tests) - You had high-risk features at diagnosis, did not achieve remission after initial chemotherapy, had detectable disease before transplant, or were in second or later remission - Your liver, kidney, and heart function are within acceptable limits **You may NOT be eligible if...** - You have another active cancer - You have an uncontrolled active infection - Your heart function (ejection fraction) is below 50% on echocardiogram Talk to your doctor to see if this trial is right for you.